Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab
British journal of surgery2017Vol. 104(7), pp. 926–935
Citations Over TimeTop 19% of 2017 papers
Kazunari Sasaki, Georgios Antonios Margonis, Nikolaos Andreatos, A.R.M. Wilson, Matthew J. Weiss, Christopher L. Wolfgang, Theodoros Ν. Sergentanis, Georgios Polychronidis, Jin He, Timothy M. Pawlik
Abstract
The impact of margin status varied according to the receipt of bevacizumab. Bevacizumab may have a role to play in improving outcomes among patients with more advanced disease.
Related Papers
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer(2012)
- → Two Cases of Leg Ulcer Caused by Bevacizumab(2017)1 cited
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)